title: This supplement provides an overview of the development of perampanel, the first non-competitive AMPA-type glutamate receptor antagonist to be developed as an adjunctive treatment for refractory partial-onset seizures. Introduction.
authors.affiliation: Sahlgrenska Academy, Gothenburg, Sweden. elinor.ben-menachem@neuro.gu.se
authors.forename: E
authors.initials: E
authors.lastname: Ben-Menachem
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006801:Humans; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*
chemical_list: D000927:Anticonvulsants; D018091:Receptors, AMPA